Login to Your Account



In The Clinic NEWS
SHANGHAI – Hutchison China Meditech Ltd., also known as Chi-Med, said this month that phase III trials would be terminated for its lead candidate, HMPL-004, a botanical treatment for ulcerative colitis (UC).

Given a lift by phase I/IIa data with KTE-C19, its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for aggressive non-Hodgkin's lymphoma, Kite Pharma Inc. plans a pivotal study early next year in diffuse large B-cell lymphoma (DLBCL).

Shares of Regado Biosciences Inc. (NASDAQ:RGDO) fell 60.2 percent Monday, closing at $1.13, after the company permanently terminated enrollment in a phase III trial of its lead program, the anticoagulant Revolixys Kit (REG1), following a string of serious allergic events found by its data and safety monitoring board (DSMB).
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: